Biotechnology

A new partnership leverages in vivo screening to find novel obesity targets, aiming to revolutionize a market projected to exceed $100 billion.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

With record growth and a fortified cash position, ElevateBio combines AI-driven discovery and industrial-scale manufacturing to power the gene therapy boom.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

CEO Werner Lanthaler will present FairJourney Bio's data-driven antibody discovery platform at the elite J.P. Morgan conference, signaling major growth.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Biotech leader Arrowhead Pharmaceuticals prices upsized offerings, signaling strong investor confidence and fueling its next wave of RNAi therapies.

The pharmaceutical giant is expanding its partnership with Veeva, adopting a next-gen CRM with agentic AI to transform its global commercial execution.